High-Concentration Anti-BAFFR Formulation With Low Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions of anti-BAFFR antibodies suffer from chemical and physical instabilities during storage, leading to antibody aggregation and reduced shelf life, which can cause immune responses in patients and are not suitable for high-concentration subcutaneous administration.
Innovation Solution
Aqueous compositions comprising anti-BAFFR antibodies with specific CDR sequences, stabilizers like sucrose or trehalose, buffering agents such as histidine or citrate, surfactants like polysorbate 20, and optionally amino acids like arginine, formulated at pH 5.0-7.0, minimizing aggregation and ensuring stability for subcutaneous use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If high concentration of antibody is formulated, then dosing volume is reduced and delivery time is minimized, but shelf life is shortened and biological activity is lost due to chemical and physical instabilities
Solution Approach 1:
The patent introduces stabilizers (sugars like sucrose and trehalose, polyols like mannitol and sorbitol, amino acids like arginine and glycine) as intermediary substances that mediate between the high-concentration antibody formulation and the storage environment. These stabilizers form protective complexes with the antibody molecules, preventing aggregation and chemical degradation while maintaining high concentration, thus enabling both rapid dosing and long-term stability.
Solution Approach 2:
The patent systematically optimizes multiple formulation parameters including pH (adjusted to 5.0-7.0 using buffers like histidine, citrate, or succinate), ionic strength, and excipient concentrations. By changing these physical and chemical parameters, the formulation achieves a stable state that prevents antibody degradation even at high concentrations, resolving the contradiction between dosing speed and storage reliability.
2Quantity of substance
If high concentration of antibody is formulated, then dosing volume is reduced, but aggregation occurs leading to increased immune response and safety concerns
Solution Approach 1:
Surfactants (polysorbate 20, poloxamer 188, hydroxyproyl-β-cyclodextrin) are introduced as intermediary substances that adsorb at the interface between antibody molecules, preventing direct interaction that would lead to aggregation. These surfactants form protective barriers around the antibody molecules, enabling high concentration formulation without aggregation-induced immune responses.
Solution Approach 2:
The patent removes or minimizes factors that promote aggregation by carefully selecting excipients with appropriate charge characteristics and hydrophobicity. The formulation extracts harmful interactions between antibody molecules by introducing stabilizing excipients that preferentially interact with the antibody surface, thereby preventing aggregation even at high concentrations.
3Ease of manufacture
If conventional formulation is used, then manufacturing is simpler, but aggregation and degradation occur during storage
Solution Approach 1:
The patent creates a composite pharmaceutical formulation by combining the antibody with multiple stabilizing excipients (sugars, polyols, amino acids, buffers, and surfactants) in specific ratios. This composite system provides synergistic protection against aggregation and degradation while maintaining ease of manufacture through a single-step mixing process, resolving the contradiction between manufacturing simplicity and compositional stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions maintain high antibody concentrations with minimal aggregation, providing stable and bioactive formulations suitable for subcutaneous administration, reducing patient intervention time and safety concerns.
Implementation Method 1
The aqueous compositions of the invention comprise high concentration of anti-BAFFR antibodies, but no or essentially no aggregated antibodies and are thus particularly suitable for subcutaneous administration... (ii) sucrose, trehalose or mannitol as a stabilizer
Implementation Method 2
The aqueous compositions of the invention comprise high concentration of anti-BAFFR antibodies... (iii) histidine, citrate or succinate as a buffering agent
Implementation Method 3
The aqueous compositions of the invention comprise high concentration of anti-BAFFR antibodies... (iv) polysorbate 20, poloxamer 188 or hydroxyproyl-b-cyclodextrin as a surfactant
Data Source
AI summary
Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.